Organisation paid for research Program year 2024 Source: CMS Open Payments

Accel Clinical

Neither a doctor nor a teaching hospital

Research payments

$43,965

14 payments

Through program year 2024, Accel Clinical is reported as receiving $43,965 in research payments, across 14 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$1,850	2
2023	Research	$14,000	1
2022	Research	$10,500	4
2021	Research	$17,615	7

Breakdown

Who paid Research payments · program years 2021–2024

Deciphera Pharmaceuticals Inc. $28,115 11 payments
Teva Pharmaceuticals USA, Inc. $15,850 3 payments

Studies the money was for Research payments · program years 2021–2024

A Phase 1 Study of the Pharmacokinetics Safety and Tolerability of Ripretinib in Subjects With Hepatic Impairment Compared to Healthy Control Subjects $17,615 7 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy $15,850 3 payments
An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination with Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced or Metastatic Solid Tumors $10,500 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.